efficacy of oral semaglutide articles and safety by subgroups of patient characteristics in the PIONEER phase 3 programme Efficacy and safety of once – oral semaglutide phase 3 Efficacy

Although metformin is a pharmacological option for patients living with obesity and PCOS, it does not significantly reduce weight or modify fat distribution

Unfortunately, Novo Nordisk is unlikely to do this

It is indicated for individuals with obesity (Body Mass Index [BMI] of 30 kg/m or greater) or those who are overweight (BMI of 27 kg/m or greater) with at least one weight-related comorbidity, such as high blood pressure, type 2 diabetes, or high cholesterol

Bland, protein-rich foods are usually better tolerated

While compounded medications are not FDA-approved, generic medications are FDA-approved

PK, porokeratosis